 REDWOOD CITY, Calif., Sept. 02, 2021 GLOBE NEWSWIRE -- Bolt Biotherapeutics Nasdaq: BOLT, a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present a corporate update and conduct meetings with the investment community at four upcoming virtual investor conferences in September: 